Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections, and to prevent initial or recurrent attacks of rheum

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the 3-year open-label extension study of AUSTEDO® (deutetrabenazine) Tablets that studied patients with tardive dyskinesia (TD) will be presented at the 2021 American Psychiatric Association (APA) Virtual Annual Meeting, being held online from May 1-3. The new data includes three abstracts that examine the long-t

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting

The stock price of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) increased 5.09% as it went from $10.12 to $10.64. This is why it happened.

TEVA Stock: From $10.12 To $10.64 Explanation

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first available 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of Absorica®1 (isotretinoin) capsules for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. “Teva's fir

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States

TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year.

TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down

Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q1 2021 Results - Earnings Call Transcript

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) CEO said that its offers to help manufacture coronavirus vaccines were turned down by major vaccine makers, despite having production capacity ready to deploy, Kare Schultz, CEO told the Financial Times. Teva has production facilities that can package, and fill and finish, vaccine vials.

Major COVID-19 Vaccine Makers Reject Teva Pharmaceutical's Offer For Jab Manufacture Help: FT

Increased competition for several of its top products continued to affect the drugmaker's performance in Q1.

What's Behind Teva's Mixed Q1 Results

Israel's Teva Pharmaceutical Industries is not likely to reach deals with COVID vaccine makers to co-produce the vaccines although discussions are still ongoing, chief executive Kare Schultz told Reuters.

Exclusive: Teva Pharm unlikely to reach deals to co-produce vaccines -CEO

Shares of Teva Pharmaceutical Industries Ltd. gained 0.6% in premarket trading after the drug maker beat earnings expectations for the first quarter, even though sales of its multiple-sclerosis drug continue to dwindle.

Teva's stock gains after it beats earnings expectations

Israel-based Teva Pharmaceutical Industries reported first-quarter profit that met estimates on Wednesday and said it was on track to meet its 2021 targets due to growth in Huntington's disease treatment Austedo and migraine product Ajovy.

Teva Pharm first quarter profit meets estimates, reaffirms 2021 outlook

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2021. Mr. Kåre Schultz, Teva's President and CEO, said, "As the COVID-19 pandemic continues to impact the world and our industry, our employees continue to work together to meet the needs of our customers and patients, all while we remain focused on our long-term goals and laying the foundation for future growth. "We have improved our profitability

Teva Reports First Quarter 2021 Financial Results

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four new posters examining long-term analyses of AUSTEDO® (deutetrabenazine) tablets and clinical outcome measures in schizophrenia will be presented at the upcoming 2021 American Psychiatric Association (APA) Annual Meeting taking place May 1-3, 2021. “These analyses support our ongoing efforts to improve the lives of people

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting

TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 1000 mg strength generic version of Casana®1 (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the U.S. Ulcerative colitis (UC) results in inflammation or swelling of the rectum (the area between the colon and the anus). This inflammation

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States

Johnson & Johnson

AbbVie

Endo International

Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the start of multibillion-dollar trial.

J&J, other drugmakers go to trial in California in $50 billion case over 'deadly legacy' of opioids

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 19 presentations examining clinical and real-world data for AJOVY® (fremanezumab-vfrm) injection and AUSTEDO® (deutetrabenazine) tablets will be presented at the upcoming 2021 American Academy of Neurology (AAN) Virtual Annual Meeting, taking place April 17-22. “We are committed to improving the lives of patients and

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva's Ongoing Commitment to Neurology

MONTRÉAL--(BUSINESS WIRE)--AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe.

Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults

AMSTERDAM--(BUSINESS WIRE)--Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK. Introducing Seffalair Spiromax and BroPair Spiromax The launch of

Teva receives EU Marketing Authorisation for Seffalair® Spiromax® and BroPair® Spiromax® (salmeterol xinafoate / fluticasone propionate)

Abercrombie & Fitch

Pfizer

Danaher

Flexion Therapeutics

Jazz Pharmaceuticals

With the trading day approaching halfway over, the broad markets were trading marginally positive.

Abercrombie, Pfizer, Teva and More of Wednesday Afternoon Analyst Calls

TEL AVIV--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the first quarter on Wednesday, April 28, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-966-1396; Israel 1-809-203

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 2021

TORONTO--(BUSINESS WIRE)--Teva Canada today unveiled new resources and programming to support the mental health challenges caregivers often experience.

Teva Canada Amplifies Commitment to Canadian Caregivers

Kirkland Lake Gold

OrganiGram Holdings Inc.

Ping Identity Holding Corp

Sirius XM Holdings Inc

Building wealth is easy when you own great businesses.

Got $50? 5 of the Best Stocks to Buy Right Now

Goodyear Tire & Rubber

SSR Mining

Value stocks have historically outperformed during economic recoveries -- and these companies look poised to shine under the new administration.

4 Value Stocks That Can Double in a Biden Bull Market

TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide ophthalmic suspension 1% works by decreasing the amount of fluid within the

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States

AGNC Investment

These deeply discounted stocks are perfect for patient investors.

News for Teva Pharmaceutical Stock (TEVA)